Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 5/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8553047 | 0.85 | ESRRG (0.38) | L3MBTL1CA2 | |
| SCHEMBL20487133 | 0.83 | MAPT (0.35) | — | |
| SCHEMBL991813 | 0.78 | HDAC1 (0.36) | L3MBTL1 | |
| SCHEMBL16208901 | 0.78 | PSMD10 (0.35) | CA1CA2 | |
| SCHEMBL206993 | 0.77 | ACHE (0.34) | L3MBTL1 | |
| SCHEMBL16216333 | 0.76 | GRM2 (0.39) | PPARA | |
| SCHEMBL20852620 | 0.76 | GRM2 (0.39) | PPARA | |
| SCHEMBL304721 | 0.76 | LMNA (0.32) | — | |
| SCHEMBL26961859 | 0.74 | L3MBTL1 (0.46) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL6284923 | 0.74 | CA14 (0.33) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703825-B2 | Compounds, use thereof as medicaments, and method of preparation thereof | UNIVERSITE DE LORRAINE (FR) | 2014-04-22 | — | — | US | disclosed |
| US-20110184070-A1 | NOVEL COMPOUNDS, USE THEREOF AS MEDICAMENTS, AND METHOD OF PREPARATION THEREOF | UNIVERSITE HENRI POINCARE NANCY 1 (FR) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184070-A1 | NOVEL COMPOUNDS, USE THEREOF AS MEDICAMENTS, AND METHOD OF PREPARATION THEREOF | CYP11B2, NPM1, B2M | S1PR1 1864/4885S1PR4 2357/4885S1PR3 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.